Oncology Evolved

with off-the-shelf cellular therapies for cancer

PIPELINE

Wugen Pipeline

PRE-CLINICAL

CLINICAL

AML

WU-NK-101

Head & Neck Cancer

WU-NK-101 + Cetuximab

Melanoma

WU-NK-101 (post-checkpoint inhibitor)

Solid Tumors

WU-NK-201

T-ALL

WU-CART-007

LATEST NEWS

Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials

Proceeds to advance clinical development of WU-NK-101 for relapsed/refractory AML, and initiate studies in solid tumor indications. Oversubscribed Series B…

Read more
Siteman
Cell-based immunotherapy shows promise against melanoma

Source: SITEMAN Cancer Center, Julia Evangelou Strait, June 2021.

Read more
OPTIMIZED BY EVOLUTION

Wugen is developing off-the-shelf cellular therapies for cancer

Radio Button Off
About Wugen

Wugen is a clinical-stage biotechnology company

Flask
Science

Cellular therapies originating from healthy donors

People
Careers

Come join our growing teams in San Diego and St. Louis